Philadelphia Pharmaceuticals (PHIL) Stock Overview
Develops, manufactures, and markets human pharmaceutical products, cosmetics, and medical devices of various therapeutic categories in Jordan. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
PHIL Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.Read more
Philadelphia Pharmaceuticals Company Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | د.أ1.50 |
| 52 Week High | د.أ1.70 |
| 52 Week Low | د.أ1.36 |
| Beta | -0.037 |
| 1 Month Change | -5.66% |
| 3 Month Change | -5.06% |
| 1 Year Change | 8.70% |
| 3 Year Change | 8.70% |
| 5 Year Change | 11.94% |
| Change since IPO | 115.52% |
Recent News & Updates
Recent updates
Shareholder Returns
| PHIL | JO Pharmaceuticals | JO Market | |
|---|---|---|---|
| 7D | -0.7% | -1.1% | 1.8% |
| 1Y | 8.7% | 17.6% | 54.2% |
Return vs Industry: PHIL underperformed the JO Pharmaceuticals industry which returned 17.6% over the past year.
Return vs Market: PHIL underperformed the JO Market which returned 54.2% over the past year.
Price Volatility
| PHIL volatility | |
|---|---|
| PHIL Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 5.8% |
| Market Average Movement | 4.2% |
| 10% most volatile stocks in JO Market | 5.8% |
| 10% least volatile stocks in JO Market | 2.4% |
Stable Share Price: PHIL's share price has been volatile over the past 3 months compared to the JO market.
Volatility Over Time: Insufficient data to determine PHIL's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 129 | Jamal Ishaq Abu Al Hawa | www.philapharma.com |
Philadelphia Pharmaceuticals Company develops, manufactures, and markets human pharmaceutical products, cosmetics, and medical devices of various therapeutic categories in Jordan. The company provides products for skin related disorders, including anti-lice and scabicides preparations, antiseptics and disinfectants, bleaching and hyperpigmentation disorders preparations, emollients and protectives, keratolytics/topical psoriasis treatment preparations, and skin healing agents, as well as agents for dermatitis; and topical acne preparation, anti-pruritic, anti-viral, plain antifungal and anti-infective, plain steroid, steroids with antifungal/anti-infective combination, and skin recoloring products. It also offers products for women health, such as vaginal antifungals, alkalinizing and cleansing agents, antimicrobials, germicidal fungicidal, antiseptics and hemostatic, and vaginal progesterone; and products in the areas of alimentary, gastrointestinal system, anti-inflammatory, analgesic, antipyretic, dental-oropharyngeal, hair care, local anesthetics, and respiratory system, as well as supplements and health care-OTC products, and hemorroidal and anal fissure preparations.
Philadelphia Pharmaceuticals Company Fundamentals Summary
| PHIL fundamental statistics | |
|---|---|
| Market cap | د.أ11.25m |
| Earnings (TTM) | د.أ1.01m |
| Revenue (TTM) | د.أ9.17m |
Is PHIL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PHIL income statement (TTM) | |
|---|---|
| Revenue | د.أ9.17m |
| Cost of Revenue | د.أ4.66m |
| Gross Profit | د.أ4.51m |
| Other Expenses | د.أ3.50m |
| Earnings | د.أ1.01m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.13 |
| Gross Margin | 49.15% |
| Net Profit Margin | 10.96% |
| Debt/Equity Ratio | 13.0% |
How did PHIL perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/15 15:52 |
| End of Day Share Price | 2026/04/09 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Philadelphia Pharmaceuticals Company is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.